Eli Lilly and Company, Insmed, Johnson & Johnson, Merck & Co., Inc., AbbVie, Pfizer, and SELLAS Life Sciences Group are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell prescription and other medicines. For investors, they offer exposure to the pharmaceutical industry, and their value can be influenced by clinical-trial results, regulatory approvals, patents, and drug pricing. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of NYSE LLY traded down $26.98 during trading on Thursday, reaching $1,355.77. 1,492,783 shares of the company traded hands, compared to its average volume of 2,950,260. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The stock has a market cap of $1.28 trillion, a P/E ratio of 44.02, a PEG ratio of 1.69 and a beta of 0.40. The firm's fifty day simple moving average is $1,258.86 and its 200 day simple moving average is $1,115.99. Eli Lilly and Company has a 12-month low of $850.51 and a 12-month high of $1,475.25.
Read Our Latest Research Report on LLY
Insmed (INSM)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
NASDAQ:INSM traded up $22.12 on Thursday, reaching $141.93. The company's stock had a trading volume of 9,778,967 shares, compared to its average volume of 3,025,465. The stock has a 50 day moving average price of $110.51 and a 200 day moving average price of $122.84. Insmed has a 12-month low of $90.39 and a 12-month high of $212.75. The firm has a market cap of $31.14 billion, a price-to-earnings ratio of -50.33 and a beta of 0.83. The company has a quick ratio of 2.59, a current ratio of 2.86 and a debt-to-equity ratio of 0.77.
Read Our Latest Research Report on INSM
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of NYSE JNJ traded down $6.14 during trading hours on Thursday, reaching $266.56. The stock had a trading volume of 4,317,400 shares, compared to its average volume of 7,939,087. Johnson & Johnson has a fifty-two week low of $199.90 and a fifty-two week high of $290.25. The firm has a market cap of $641.70 billion, a price-to-earnings ratio of 40.44, a PEG ratio of 2.75 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average of $267.42 and a 200-day moving average of $250.61.
Read Our Latest Research Report on JNJ
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of Merck & Co., Inc. stock traded down $4.59 during trading on Thursday, hitting $133.19. 5,233,512 shares of the company were exchanged, compared to its average volume of 10,501,186. The stock has a market capitalization of $328.35 billion, a price-to-earnings ratio of 137.71, a P/E/G ratio of 6.57 and a beta of 0.13. The firm has a 50 day moving average price of $145.73 and a 200 day moving average price of $129.11. Merck & Co., Inc. has a fifty-two week low of $93.90 and a fifty-two week high of $156.92. The company has a quick ratio of 1.14, a current ratio of 1.35 and a debt-to-equity ratio of 1.11.
Read Our Latest Research Report on MRK
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
AbbVie stock traded down $3.07 during midday trading on Thursday, hitting $282.94. 2,042,783 shares of the stock were exchanged, compared to its average volume of 6,258,335. The firm has a market cap of $500.13 billion, a P/E ratio of 48.77, a P/E/G ratio of 1.33 and a beta of 0.20. AbbVie has a 1 year low of $190.75 and a 1 year high of $302.93. The company has a 50 day moving average price of $277.84 and a two-hundred day moving average price of $241.96.
Read Our Latest Research Report on ABBV
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Pfizer stock traded down $0.43 during trading hours on Thursday, hitting $27.62. 17,987,494 shares of the company traded hands, compared to its average volume of 39,601,770. Pfizer has a 1-year low of $23.62 and a 1-year high of $31.44. The company has a quick ratio of 1.10, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. The firm's 50-day simple moving average is $28.83 and its two-hundred day simple moving average is $27.02. The firm has a market cap of $157.46 billion, a P/E ratio of 39.54, a P/E/G ratio of 1.87 and a beta of 0.31.
Read Our Latest Research Report on PFE
SELLAS Life Sciences Group (SLS)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Shares of SLS traded down $3.21 during midday trading on Thursday, reaching $14.74. 25,750,814 shares of the stock were exchanged, compared to its average volume of 8,568,321. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -73.48 and a beta of 2.73. The firm has a 50 day simple moving average of $11.09 and a 200-day simple moving average of $8.94. SELLAS Life Sciences Group has a 12-month low of $1.39 and a 12-month high of $24.89.
Read Our Latest Research Report on SLS
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.